

CNCR

Range Cancer Therapeutics ETF

Fund Description

CNCR tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products.

FactSet Analyst Report

The security is being delisted. The last day of trading on an exchange is May 26, 2025. CNCR takes an approach to niche coverage within the healthcare sector. It provides equal-weighted exposure to companies that generate their revenue from oncology products or are in constant development and production of cancer therapeutic medicine. Cancer Therapeutics is a term used to refer to the wide range of treatments and interventions used to treat various kinds of cancer. Equal weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space. Prior to June 20, 2023, the fund tracked the Loncar Cancer Immunotherapy Index and traded under the name Loncar Cancer Immunotherapy ETF. Effective October 20, 2023, the Loncar China BioPharma ETF that traded under the symbol CHNA merged into CNCR, acquiring its assets and expanding the funds exposure to China. Before June 3, 2024, the fund's index name swapped Cancer for Oncology, keeping the strategy unchanged.

